We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.

Delisted

BLPH was delisted on the 13th of October, 2023.

26 hedge funds and large institutions have $26.5M invested in Bellerophon Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% more funds holding

Funds holding: 2626 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

9% less capital invested

Capital invested by funds: $29.1M → $26.5M (-$2.66M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
26
Holders Change
Holders Change %
0%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
3
Increased
7
Reduced
6
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVM
26
Arch Venture Management
Illinois
-$631K -64,377 Closed
SM
27
Sabby Management
Florida
-$202K -20,594 Closed
BCM
28
Bridgeway Capital Management
Texas
-$103K -10,533 Closed
Morgan Stanley
29
Morgan Stanley
New York
+$489 +51 +155%

BLPH Hedge Fund Activity: Q2 2019 in Review

26 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2019, worth a combined $26.5M — down 9.1% from $29.1M a quarter earlier.

Fund positioning in BLPH was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 6 trimmed.

The largest buyer was Telemetry Investments, adding an estimated $189K. The largest seller was Arch Venture Management, exiting entirely with an estimated $631K sold.

  • 26 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $26.5M of Bellerophon Therapeutics, Inc. stock for Q2 2019, down 9.1% quarter-over-quarter.
  • 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2019 and 3 closed out, a net change of 0 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q2 2019 was Telemetry Investments, an estimated $189K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q2 2019 was Arch Venture Management, an estimated $631K sold.

Based on aggregated 13F filings for Q2 2019.